Articles Archives

Prioritizing Commercialization Decisions in Early Stages of Advanced Therapy Development

Successful biopharmaceutical organizations begin developing a commercialization strategy in early stages. Instead of waiting until their advanced therapy or biologics product is closer to pivotal trial stages, developers should confront these decisions as soon as possible. In a recent interview with Pharmaceutical Commerce, Gwen Erskine, Senior Director of Consulting Services at Cryoport Systems, illustrates why prioritizing commercialization readiness during early phases of development optimizes profitability, flexibility, and risk management.

Read More

Cryoport Systems Wins Healthcare & Pharmaceutical Supply Chain Excellence Award for Advancing Patient Safety Through ISO 21973-Certified Supply Chain

Cryoport Systems is proud to announce that it has received the Healthcare & Pharmaceutical Supply Chain Excellence Award at the 2026 Supply Chain Excellence USA Awards. Part of a globally recognized awards program with a nearly 30-year legacy, the Supply Chain Excellence Awards recognize organizations that demonstrate innovation, collaboration, and measurable impact through supply chain excellence.

Read More

Continuing the Conversation: What Quality Leaders Need to Know About Building Supply Chains for Advanced Therapies

Following Pharmaceutical Commerce’s podcast with Adam Fox, Chief Quality & Regulatory Affairs Officer at Cryoport Systems, we wanted to explore several topics that deserve a deeper look. As cell and gene therapies continue to advance, quality leaders are discovering that supply chains have become an extension of the quality system itself.

Read More

Beyond Clinical Success: Bianca Gustafson on Building Supply Chains That Scale

In a recent Contract Pharma interview, Bianca Gustafson, Senior Director of Program Management at Cryoport Systems, shared an important perspective on the transition from clinical development to commercialization. According to Gustafson, a common mistake organizations make is assuming that commercial readiness is an extension of clinical operations, when actually commercialization requires a full-on shift in how supply chains are designed and scaled.

Read More

Now Available On Demand: Preventing Advanced Therapy Program Delays with Early Supply Chain Strategy

Advanced therapy programs move through development under intense pressure. Teams are working to reach the clinic, generate data, satisfy regulatory expectations, scale operations, and ultimately deliver therapies to patients who may have limited or no other options. In that environment of competing priorities, all of which are important at the same time, supply chain decisions can become easy to defer. But as a recent roundtable webinar with XTalks made clear, decisions around cryopreservation, logistics, packaging qualification, site readiness, and documentation are not just operational details that can be solved later.

Read More

New eBook: Flexible Infrastructure for Smarter Scale in Advanced Therapies

Advanced therapy developers are being asked to do more with less. Programs need to move faster, reach more patients, support more geographies, and stay ready for evolving regulatory expectations, all while capital remains tightly managed. Cryoport Systems’ new eBook, Flexible Infrastructure: Minimizing CapEx for Smarter Scale in Advanced Therapies, explores that question across the advanced therapy lifecycle. The eBook looks at how developers can preserve capital, reduce operational risk, and avoid overbuilding fixed infrastructure before their programs are ready to use it. 

Read More

Mark Sawicki Joins Base to Base Biotech to Discuss the Future of Cell and Gene Therapy Logistics

Mark Sawicki, President and CEO of Cryoport Systems, recently joined host Jim Cornall on the Base to Base Biotech podcast for a wide-ranging conversation on the evolving cell and gene therapy landscape and the role of specialized supply chain infrastructure in supporting patient access.

Read More

Dominic Clarke on Reducing Variability Before it Becomes a Problem

As cell therapy programs advance, the pressure on supply chains doesn’t usually come from a single breaking point. It builds gradually, often in ways that aren’t immediately visible during early development. In a recent episode of Beyond Biotech, the podcast from Labiotech, Dominic Clarke, Vice President of IntegriCell® Technical Operations at Cryoport Systems, shares what that progression looks like.

Read More

Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break

As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up. A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.

Read More